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To identify genetic susceptibility factors conferring increased risk of venous thrombosis (VT), we conducted amultistage study, following
results of a previously published GWAS that failed to detect loci for developing VT. Using a collection of 5862 cases with VT and 7112
healthy controls, we identiﬁed the HIVEP1 locus on chromosome 6p24.1 as a susceptibility locus for VT. Indeed, the HIVEP1 rs169713C
allele was associated with an increased risk for VT, with an odds ratio of 1.20 (95% conﬁdence interval 1.13–1.27, p ¼ 2.86 3 109).
HIVEP1 codes for a protein that participates in the transcriptional regulation of inﬂammatory target genes by binding speciﬁc DNA
sequences in their promoter and enhancer regions. The current results provide the identiﬁcation of a locus involved in VT susceptibility
that lies outside the traditional coagulation/ﬁbrinolysis pathway.We recently reported results of the only GWAS performed
to date on venous thrombosis (VT) including deep vein
thrombosis (DVT) and pulmonary embolism (PE).1 In a
ﬁnal analysis of 419 VT patients and 1228 healthy individ-
uals typed with the Illumina Sentrix HumanHap300 array
for 291,872 SNPs, only ﬁve SNPs reached statistical signif-
icance at a ¼ 3.47 3 107. These SNPs were located within
two well-established susceptibility loci for VTE, F5 (MIM
612309) and ABO (MIM 110300).2 In the current report,
we pursued, by standard TaqMan genotyping technology
(Applied Biosystems), the follow-up of nine SNPs that
did not reach genome-wide signiﬁcance but were never-
theless associated with VT at p < 1 3 105, corresponding
to a false discovery rate estimate of 16% (Table 1). These
nine SNPs were investigated in the MARTHA study,1
composed of 1129 VT cases and 801 controls of European
origin.
Of these nine SNPs, three showed signiﬁcant association
with VT after Bonferroni correction for the number of
tested SNPs (Table 1). Two of them, rs169713 (p ¼ 2.08 3
105) and rs9380643 (p ¼ 1.98 3 106), are located on
chromosome 6p24.1, in the vicinity of the HIVEP1 (MIM
194540) locus, whereas the third one, rs11210892
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1p34.1. Consequently, these three SNPs were further
examined for support of association with VT in a third
independent sample, the FARIVE study,1 composed of
561 cases with VT and 564 controls of French origin. As a
result, none of these SNPs was signiﬁcantly associated
with VT in FARIVE (Table 1), although the rs169713-C
allele was more frequent in cases compared to controls
(0.24 versus 0.21, p ¼ 0.089), as also observed in the
GWAS and MARTHA samples (Figure 1). Because no evi-
dence for heterogeneity across the three studies (p¼ 0.250)
was detected by use of the Mantel-Haenszel method, and
because the FARIVE study had a power of only ~40%
(calculated by the Cats software3) to detect the observed
allele-frequency differences at a signiﬁcance level of 0.05,
rs169713 was further investigated in the MEGA study,4
composed of 3753 VT patients and 4519 controls of Dutch
origin. In MEGA, the rs169713-C allele was signiﬁcantly
more frequent in cases than in controls (0.22 versus 0.20,
p ¼ 0.014) (Figure 1, Table S1 [available online]), even if
the association was slightly weaker as compared to the
other studies.
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Table 1. SNPs Associated at p < 105 with VT in the GWAS Scan and Their Replication in the Independent MARTHA and FARIVE Studies
GWAS MARTHA FARIVE
MAFa MAFa MAFa
Chr. Gene(s) rsID Position Alleles
Controls
(n ¼ 1228)
Cases
(n ¼ 419) p Valueb
Controls
(n ¼ 801)
Cases
(n ¼ 1129) p Valueb
Controls
(n ¼ 607)
Cases
(n ¼ 607) p Valueb
1p34.2 PTPRF rs11210892 43 872 671 A/G 0.32 0.40 6.70 3 106 0.32 0.37 1.83 3 103 0.33 0.33 0.811
3q26.31 TNIK rs10936688 172 656 249 A/G 0.36 0.44 3.15 3 106 0.39 0.37 0.187
6p24.1 HIVEP1 rs169713 12 028 503 T/C 0.21 0.28 7.24 3 106 0.23 0.29 2.08 3 105 0.21 0.24 0.089
rs9380643 12 038 473 C/T 0.22 0.30 2.44 3 106 0.24 0.31 1.98 3 106 0.24 0.26 0.227
7p15.3 IL6/TOMM7 rs10229457 22 767 325 G/A 0.29 0.38 1.05 3 106 0.34 0.36 0.128 - - -
8p21.3 ATP6V1B2/LZTS1 rs952148 20 135 799 C/T 0.11 0.06 1.35 3 106 0.10 0.11 0.459 - - -
12p12.1 ST8SIA1 rs2268861 22 280 741 G/A 0.32 0.24 1.82 3 106 0.31 0.29 0.231 - - -
16q22.1 NFATC3 rs12598 66 783 016 G/A 0.08 0.04 7.64 3 106 0.06 0.05 0.074 - - -
22q13.31 Gene desert rs4823511 46 823 885 A/G 0.24 0.16 5.45 3 106 0.22 0.21 0.421 - - -
SNPs that did not pass the genome-wide significance level of 1.71 3 107 but showed suggestive evidence of association (p < 105) were investigated in the MARTHA study. SNPs that passed the Bonferroni-corrected
significance level (p < 5.6 3 103) in MARTHA were further tested for association with VT in FARIVE.
a MAF, minor allele frequency.
b p values of the Cochran-Armitage trend test.
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Figure 1. Forest Plot of the Association
between rs169713 and VT Risk
Squares represent odds ratios with their
95% conﬁdence interval under the as-
sumption of additive allele effects. The
whole odds ratio estimate was obtained
from a combined analysis of all individual
data sets after checking for homogeneity
by use of the Mantel-Haenszel method.allele was signiﬁcantly more frequent in cases than in
controls (0.24 versus 0.21) and was associated with a
combined odds ratio of 1.20 (95% conﬁdence interval
1.13–1.27, p ¼ 2.86 3 109) for VT. This effect was more
pronounced (p ¼ 0.001) in the GWAS and the MARTHA
study (OR ¼ 1.419 [1.266–1.591], p ¼ 1.85 3 109) as
compared to the FARIVE and MEGA studies (OR ¼ 1.110
[1.035–1.190], p ¼ 3.38 3 103). This was due to the fact
that the frequency of the rs169713-C allele was higher in
GWAS and MARTHA cases compared to FARIVE and
MEGA cases, whereas its frequency was very homogeneous
in the four control groups (Figure 1). Cases from the GWAS
and MARTHA are patients referred to thrombophilia
centers, whereas patients from FARIVE and MEGA were
recruited from the general population. The former are
often considered to be enriched in familial forms,5 a likely
explanation for the observed higher frequency of the
VT-disease-associated allele in this group. The rs169713-C
allele association did not show any evidence for heteroge-
neity according to the age at onset, VT status (idiopathic
versus nonidiopathic, DVT versus PE), or known risk
factors for VT, such as sex, oral contraceptives, FV Leiden
mutation, and ABO blood group (Tables S1–S8).
rs169713 maps to the pseudogene LOC100129761 and
is 92 kb distant in 50 orientation from the HIVEP1 gene.
In the initial GWAS scan, the SNP with the highest
signiﬁcance was rs9380643, also strongly associated with
VT inMARTHA. However, this SNP did not show any trend
for association in FARIVE, and linkage disequilibrium (LD)
analysis in MARTHA revealed that its effect was probably
due to its strong LD with rs169713 (D0 ¼ þ0.87, r2 ¼
0.66). rs169713 was the second lead SNP at the HIVEP1
locus in the GWAS, and several otherHIVEP1 SNPs showed
suggestive evidence of association with VT (p < 103)
(Table S8). According to public databases, there are many
other SNPs at the HIVEP1 gene locus, including several
insertion/deletion polymorphisms, which may not be
well characterized by the DNA array used in the initial
scan. LD analysis of the HapMap database via the SNAP
software6 revealed that none of the SNPs located in the
coding, intronic, and 30 untranslated regions of the gene
showed pairwise r2 > 0.32 with the rs169713, suggesting594 The American Journal of Human Genetics 86, 592–595, April 9, 2010that the HIVEP1 promoter would
probably be the candidate region har-
boring the functional variant(s). In
silico analyses with the MatInspec-
tor7 and Patch tools both suggestedthat the rs169713-C allele potentially creates a binding
site for AHR/ARNT transcription factors (factors activated
by exposure to dioxin); however, additional ﬁne-mapping
studies and in-depth molecular functional studies are war-
ranted for the detection of functional variant(s) causally
related to VT phenotypes.
HIVEP1 belongs to the HIVEP gene family encoding very
large sequence-speciﬁc DNA-binding proteins containing
multiple zinc ﬁngers.8,9 These genes have been reported
to directly participate in the transcriptional regulation
of a variety of genes by binding to their promoter NF-kB
consensus sequences. Closely related sequences are found
in the promoter enhancer elements of class I MHC, inter-
leukin-2 receptor, and interferon-b genes, the latter being
also linked to the inﬂammatory Toll-like receptor signaling
pathway. HIVEP1 itself regulates the transcription of genes
such as HIV, H-2K, and IFN-B.9 As part of an ongoing
genome-wide expression analysis in monocytes of 1490
healthy individuals (unpublished data), an ontology anal-
ysis using the PANTHER software revealed that genes
whose expression were strongly correlated to HIVEP1
gene expression were particularly enriched in those
belonging to the interleukin signaling pathway. These
data, if conﬁrmed, would point to a possible role of the HI-
VEP1 locus in inﬂammation, a biological process whose
role in thrombosis-related mechanisms is increasingly
advocated.10–12 In addition, links between NF-kB and VT
through regulation of the production of microparticles
from endothelial cells and platelet activation emerged
from recent works.13,14
According to databases of expressed sequence tag
patterns, HIVEP1 is expressed in a variety of tissues. In
that respect, we observed HIVEP1 expression in endothe-
lial cells, platelets, monocytes, and macrophages from
healthy donors human blood (Figure S1) as well as in
human carotid atheroma plaques (Figure S2).
Given the the latter results and the key role of inﬂamma-
tion in atherosclerosis and its cardiovascular complica-
tions, additional investigations are warranted to assess
whether the HIVEP1 locus could also contribute to the
genetic susceptibility of cardiovascular disease pheno-
types, linking VT to arterial thrombosis.15
Using a multistage strategy, we obtained strong evidence
in favorof the implicationof theHIVEP1 locus asa candidate
forVTrisk.Toourknowledge, this study is theﬁrst toprovide
evidence of the role of a genetic variant on the risk of VT
outside the traditional coagulation/ﬁbrinolysis cascade.Supplemental Data
Supplemental Data include eight tables and two ﬁgures and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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